OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 5.18 EUR 0.39%
Market Cap: 116.3m EUR

OSE Immunotherapeutics SA
Interest Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

OSE Immunotherapeutics SA
Interest Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Expense CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
Interest Expense
€3m
CAGR 3-Years
32%
CAGR 5-Years
63%
CAGR 10-Years
54%
Valneva SE
PAR:VLA
Interest Expense
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanobiotix SA
PAR:NANO
Interest Expense
€8.5m
CAGR 3-Years
44%
CAGR 5-Years
6%
CAGR 10-Years
75%
Inventiva SA
PAR:IVA
Interest Expense
€16.7m
CAGR 3-Years
330%
CAGR 5-Years
301%
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
Interest Expense
$346k
CAGR 3-Years
46%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
Abivax SA
PAR:ABVX
Interest Expense
€18.8m
CAGR 3-Years
123%
CAGR 5-Years
81%
CAGR 10-Years
N/A
No Stocks Found

OSE Immunotherapeutics SA
Glance View

Market Cap
114m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
Not Available

See Also

What is OSE Immunotherapeutics SA's Interest Expense?
Interest Expense
3m EUR

Based on the financial report for Jun 30, 2025, OSE Immunotherapeutics SA's Interest Expense amounts to 3m EUR.

What is OSE Immunotherapeutics SA's Interest Expense growth rate?
Interest Expense CAGR 10Y
54%

Over the last year, the Interest Expense growth was -24%. The average annual Interest Expense growth rates for OSE Immunotherapeutics SA have been 32% over the past three years , 63% over the past five years , and 54% over the past ten years .

Back to Top